IMUGENE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.059 AUD | -3.28% |
|
-13.24% | -46.36% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 447M 297M |
|---|---|---|---|---|---|
| Net income 2024 * | -115M -76.51M | Net income 2025 * | -97M -64.53M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.27
x | P/E ratio 2025 * |
-4.69
x | Employees | 5 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.6% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.28% | ||
| 1 week | -11.94% | ||
| Current month | -11.94% | ||
| 1 month | -23.38% | ||
| 3 months | -46.36% | ||
| 6 months | -35.87% | ||
| Current year | -46.36% |
1 week
0.06
0.07
1 month
0.060.08
Current year
0.060.13
1 year
0.040.15
3 years
0.040.63
5 years
0.010.63
10 years
0.010.63
| Managers | Title | Age | Since |
|---|---|---|---|
Leslie Chong
CEO | Chief Executive Officer | - | 15-08-26 |
Michael Tonroe
DFI | Director of Finance/CFO | 57 | 22-08-31 |
John Byon
CTO | Chief Tech/Sci/R&D Officer | - | 23-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lesley Russell
BRD | Director/Board Member | 63 | 19-04-22 |
Jens Eckstein
BRD | Director/Board Member | 60 | 19-05-19 |
| Director/Board Member | 56 | 23-06-20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 2 M€ | -.--% | ||
| 0.00% | 7 M€ | +6.05% | - | |
| 0.00% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 0.059 | -3.28% | 15 262 908 |
| 24-06-05 | 0.061 | +1.67% | 27,746,030 |
| 24-06-04 | 0.06 | -6.25% | 44,936,680 |
| 24-06-03 | 0.064 | -4.48% | 19,444,710 |
| 24-05-31 | 0.067 | 0.00% | 9,625,162 |
Delayed Quote Australian S.E., June 06, 2024 at 02:10 am EDT
More quotes
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyâs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Calendar
2024-08-29
- Q4 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.061
AUD
Average target price
0.3533
AUD
Spread / Average Target
+479.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.36% | 296M | |
| +55.70% | 59.34B | |
| +42.95% | 40.24B | |
| -5.39% | 39.88B | |
| -5.56% | 28.55B | |
| +16.46% | 27.26B | |
| -20.56% | 19.23B | |
| +33.03% | 12.61B | |
| +25.85% | 12.28B | |
| +2.72% | 12.49B |
- Stock Market
- Equities
- IMU Stock
